Sepsis, September 2025 edition

This translational study identified IGFBP6 as a circulating regulator associated with sepsis diagnosis and prognosis. IGFBP6 bound PHB2 independently of IGF signaling, impaired STAT1-driven CCL2 transcription and macrophage chemotaxis, and suppressed Akt-dependent bactericidal functions. Genetic or pharmacologic rescue of the PHB2-STAT1 or Akt pathways improved bacterial clearance and survival in septic mice.

Impact: The study links a measurable circulating protein to two complementary mechanisms of immune collapse and demonstrates rescue in vivo. It is unusually strong as a biomarker-to-mechanism-to-therapy package and provides a rational basis for stratified immunorestorative interventions.

Clinical Implications: IGFBP6 could be developed as a diagnostic or prognostic biomarker and potentially as a patient-selection marker for immune-restorative therapy. However, the timing of intervention will be critical because reversal of immunosuppression may be harmful during uncontrolled hyperinflammation or in patients with distinct immune endotypes.

An AI-screened peptide, SK56, directly blocks gasdermin D N-terminal pores rather than preventing gasdermin D cleavage or IL-1β production. SK56 reduced pyroptosis and cytokine release in macrophages and human leukocytes, improved survival in LPS and CLP mouse models, and limited bystander immune activation and organoid cell death.

Impact: This is a first-in-class demonstration that execution-stage blockade of GSDMD pores can moderate pyroptosis without abolishing upstream inflammasome signaling. It connects AI-enabled peptide discovery with a novel, mechanistically precise sepsis intervention.

Clinical Implications: GSDMD pore blockers could potentially provide adjunctive control of hyperinflammation while preserving some upstream host-defense signaling. Development must address peptide pharmacokinetics, immunogenicity, tissue penetration, effects on pathogen clearance, and treatment timing across different sepsis endotypes.

InfEHR represents complete electronic health records as temporal graphs and applies deep geometric learning to infer clinical phenotypes with very few labeled examples. Across two health systems, the method substantially improved detection of culture-negative neonatal sepsis and postoperative acute kidney injury while preserving high specificity. The study addresses a major barrier in clinical AI: limited availability of high-quality manually labeled data.

Impact: This is a scalable diagnostic-AI advance that directly addresses label scarcity and targets clinically difficult, low-prevalence sepsis phenotypes. Its cross-system evaluation and marked sensitivity improvement make it highly relevant to future early-warning systems.

Clinical Implications: InfEHR-like systems could support early review of high-risk patients, especially neonates with culture-negative disease, and may help prioritize confirmatory testing or treatment reassessment. Before deployment, prospective impact studies should evaluate alert burden, calibration across hospitals, health-equity effects, and whether improved detection changes antibiotic exposure or patient outcomes.

This translational study links elevated serum N-formyl methionine to FPR1/HIF-1α activation, excessive NETosis, and sepsis-induced cardiomyopathy. Patient biomarker associations were complemented by human-cell experiments and CLP mouse studies. Genetic deletion or pharmacologic inhibition of FPR1 reduced NET formation and inflammation while improving cardiac function, mitochondrial function, and survival.

Impact: The study integrates a patient-associated biomarker with a defined host pathway and reproducible organ-protective effects in vivo. It provides a plausible bridge from NET biology to a therapeutic strategy for septic cardiomyopathy.

Clinical Implications: fMet and NET markers may help identify patients at risk for septic cardiomyopathy, while FPR1 inhibition could become an adjunctive host-directed approach. Translation requires confirmation in diverse patient cohorts, careful assessment of infection-control effects, and development of selective, clinically tolerable FPR1 inhibitors.

This reverse-translational study proposes that the lethal intoxication phase of yellow fever is driven in part by mesenteric ischemia, intestinal epithelial breakdown, and portal-system bacterial translocation, producing a secondary sepsis-like syndrome. Findings from a hamster model were supported by pathology and intestinal-injury or bacteremia markers in fatal human cases. The work reframes late yellow-fever deterioration as potentially involving treatable secondary bacterial sepsis physiology.

Impact: Although focused on yellow fever, the study provides a major infectious-disease paradigm shift: severe viral disease may transition into gut-barrier failure and secondary sepsis physiology. It offers immediately testable hypotheses for clinical monitoring, antimicrobial consideration, and intestinal-protection strategies.

Clinical Implications: In severe yellow fever, clinicians may need to assess for mesenteric ischemia, intestinal barrier failure, and secondary bacteremia rather than attributing all deterioration to viral injury. Any empiric antimicrobial strategy must be studied carefully because evidence for benefit, timing, and pathogen coverage remains incomplete.